Live from the NIH registry
Studies recruiting near Fort Collins right now
Top 25 of 154 recruiting studies, sorted by proximity — each links to its official registry page
Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma
Smoldering Plasma Cell Myeloma
Phase 3
Interventional 288 participants sought
Banner North Colorado Medical Center - Loveland Campus — Loveland, Colorado (10.4 mi)
· Sponsor: ECOG-ACRIN Cancer Research Group
Shortening Adjuvant Photon and Proton Irradiation (SAPPHIRe-II): A 4 Cohort, Randomized, Phase II Multi-center Trial Evaluating Shorter Schedules of Adjuvant Regional Nodal Irradiation Among Women and Men With Node-positive and High-risk Node-negative Invasive Breast Cancer
Breast Cancer
Phase 2
Interventional 768 participants sought
Banner MD Anderson Northern Colorado — Loveland, Colorado (10.4 mi)
· Sponsor: M.D. Anderson Cancer Center
The MITRAL II Pivotal Trial (Mitral Implantation of TRAnscatheter vaLves).
Mitral Annular Calcification, Mitral Stenosis
N/A
Interventional 210 participants sought
Uchealth Heart & Vascular Clinic Harmony Campus — Fort Collins, Colorado (2.8 mi)
· Sponsor: Mayra Guerrero
Cognitive-Behavioral Therapy and Exercise Training in Adolescents At-Risk for Type 2 Diabetes
Insulin Resistance, Depression
N/A
Interventional 300 participants sought
Colorado State University — Fort Collins, Colorado (2.8 mi)
· Sponsor: Colorado State University
Global Paradise System US Post Approval Study
Hypertension, Cardiovascular Diseases
N/A
Observational 1,000 participants sought
Medical Center of the Rockies — Loveland, Colorado (10.4 mi)
· Sponsor: ReCor Medical, Inc.
A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
Melanoma
Phase 3
Interventional 560 participants sought
UCHealth — Fort Collins, Colorado (2.8 mi)
· Sponsor: Regeneron Pharmaceuticals
A Study to Assess Adverse Events and Effectiveness of Gel Stent (XEN63) Implantation Using Ab Interno and Ab Externo Approaches in Adult Participants With Glaucoma
Primary Open Angle Glaucoma
Phase 3
Interventional 130 participants sought
Eye Center of Northern Colorado /ID# 281798 — Fort Collins, Colorado (2.8 mi)
· Sponsor: AbbVie
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8
Phase 3
Interventional 3,680 participants sought
Poudre Valley Hospital — Fort Collins, Colorado (2.8 mi)
· Sponsor: National Cancer Institute (NCI)
Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma
Classic Follicular Lymphoma, Follicular Lymphoma With Unusual Cytological Features
Phase 3
Interventional 600 participants sought
Poudre Valley Hospital — Fort Collins, Colorado (2.8 mi)
· Sponsor: National Cancer Institute (NCI)
Sex Differences in Cold-Induced Changes in Maximal Fat Oxidation
Exercise
N/A
Interventional 20 participants sought
Colorado State University — Fort Collins, Colorado (2.8 mi)
· Sponsor: Colorado State University
A Long-Term Safety Study of Elismetrep (K-304) in the Acute Treatment of Migraine
Acute Migraine
Phase 3
Interventional 1,000 participants sought
Advanced Neurosciences Research — Fort Collins, Colorado (2.8 mi)
· Sponsor: Kallyope Inc.
Reaching Rural Cancer Survivors Who Smoke Using Text-Based Program
Cigarette Smoking-Related Carcinoma
Phase 3
Interventional 600 participants sought
Banner North Colorado Medical Center - Loveland Campus — Loveland, Colorado (10.4 mi)
· Sponsor: Alliance for Clinical Trials in Oncology
Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study
Extensive Stage Lung Small Cell Carcinoma, Lung Small Cell Carcinoma, A Subtype
Phase 2
Interventional 900 participants sought
Poudre Valley Hospital — Fort Collins, Colorado (2.8 mi)
· Sponsor: SWOG Cancer Research Network
Immune Checkpoint Inhibitor Toxicity Risk Prediction in Solid Tumors
Malignant Solid Neoplasm
N/A
Observational 2,062 participants sought
Poudre Valley Hospital — Fort Collins, Colorado (2.8 mi)
· Sponsor: SWOG Cancer Research Network
Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma
Endometrial Carcinoma, Endometrial Clear Cell Adenocarcinoma
Phase 3
Interventional 360 participants sought
Banner North Colorado Medical Center - Loveland Campus — Loveland, Colorado (10.4 mi)
· Sponsor: National Cancer Institute (NCI)
Efficacy and Safety of IMVT-1402 in Adult Participants With Primary Sjogren's Disease With Moderate to Severe Systemic Disease Activity
Primary Sjögren's Syndrome
Phase 2
Interventional 180 participants sought
Site Number - 1014 — Fort Collins, Colorado (2.8 mi)
· Sponsor: Immunovant Sciences GmbH
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
PIK3CA Mutation, HER2- Negative Breast Cancer
Phase 3
Interventional 540 participants sought
Rocky Mountain Cancer Centers, LLP — Longmont, Colorado (26.4 mi)
· Sponsor: Relay Therapeutics, Inc.
A Study of Ocrelizumab Administered Subcutaneously in Participants With Multiple Sclerosis Who Switch From an Approved Anti-CD20 Therapy
Multiple Sclerosis
Phase 4
Interventional 100 participants sought
Advanced Neurology of Colorado — Fort Collins, Colorado (2.8 mi)
· Sponsor: Genentech, Inc.
A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
Gastroesophageal-junction Cancer, Monoclonal Antibody
Phase 3
Interventional 550 participants sought
Banner MD Anderson Cancer Center — Greeley, Colorado (20.6 mi)
· Sponsor: Shanghai Henlius Biotech
A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy
Age-related Macular Degeneration (AMD), Geographic Atrophy (GA)
Phase 3
Interventional 975 participants sought
Eye care Center of Northern Colorado doing business as Advanced Vision Research Institute — Longmont, Colorado (26.4 mi)
· Sponsor: Regeneron Pharmaceuticals
Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer
Oropharyngeal p16INK4a-Negative Squamous Cell Carcinoma, Stage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7
Phase 2, Phase 3
Interventional 613 participants sought
Banner North Colorado Medical Center - Loveland Campus — Loveland, Colorado (10.4 mi)
· Sponsor: National Cancer Institute (NCI)
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
B-cell Malignancy, Marginal Zone Lymphoma
Phase 1, Phase 2
Interventional 645 participants sought
Uchealth North — Fort Collins, Colorado (2.8 mi)
· Sponsor: BeOne Medicines
Mobile Health for Adherence in Breast Cancer Patients
Anatomic Stage IV Breast Cancer AJCC v8, Breast Carcinoma
N/A
Interventional 410 participants sought
Longmont United Hospital — Longmont, Colorado (26.4 mi)
· Sponsor: ECOG-ACRIN Cancer Research Group
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
Carcinoma, Non-Small-Cell Lung
Phase 3
Interventional 680 participants sought
Banner MD Anderson Cancer Center at North Colorado Medical Center ( Site 0207) — Greeley, Colorado (20.6 mi)
· Sponsor: Merck Sharp & Dohme LLC
A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration (nAMD) Treated With the Port Delivery System With Ranibizumab (PDS)
Neovascular Age-related Macular Degeneration
Phase 4
Interventional 188 participants sought
Advanced Vision Research Institute — Longmont, Colorado (26.4 mi)
· Sponsor: Genentech, Inc.